RAS-Mutant Advanced Or Metastatic Solid Tumors
ANLAdlai Nortye BiopharmaCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for AN9025 (Pan-RAS Inhibitor) in RAS-Mutant Advanced Or Metastatic Solid Tumors. The expected timing is based on the latest available company guidance and may change.
02/12/26:- First U.S. patient dosed in ongoing Ph1 MRCT of AN9025 in RAS-mutant solid tumors. 07/16/26:- First U.S. patient dosed in weekly arm. Initial Phase 1 dose-escalation data expected H1 2027. 08/14/26:- QD and QW arms are enrolling concurrently. Initial Phase Ia QD data, with a possible QW look, is expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.